chartexchange

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

GlobeNewswire Inc. | Oct 28, 2026 8:35 AM EDT

- Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -

Read original article